Lakefront Biotherapeutics NVWBO:LKFT +0.79%60 Gross Margin % is 25.95% as of Mar. 2026, which is 73% below its 10-year median of 97.33. GuruFocus rates WBO:LKFT with a GF Score™ of 60/100 and a GF Value™ of €104.25 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 738 Biotechnology companies, Lakefront Biotherapeutics NV ranks better than 95.26% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lakefront Biotherapeutics NV had a gross margin of 25.95% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Lakefront Biotherapeutics NV Gross Margin % Related Terms
Lakefront Biotherapeutics NV Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:LKFT vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Lakefront Biotherapeutics NV (WBO:LKFT) has a Gross Margin % of 25.95% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Lakefront Biotherapeutics NV and its competitors. This is 73% below median its historical median of 97.33. Over the past decade, Lakefront Biotherapeutics NV's Gross Margin % has ranged from 87.35 to 206.16. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #35 out of 738 companies in the Biotechnology industry, placing it in the top 4.7%.
Is Lakefront Biotherapeutics NV's Gross Margin % too high?
Lakefront Biotherapeutics NV's current Gross Margin % of 25.95% is 73% below median its 10-year median of 97.33. Over the past 10 years, this metric has ranged from a low of 87.35 to a high of 206.16. The Biotechnology industry median Gross Margin % is 60.94. Lakefront Biotherapeutics NV's value of 25.95% is 57.4% below this industry median. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #35 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #35 out of 738 companies for Gross Margin %. This places Lakefront Biotherapeutics NV in the top 5% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.94. Lakefront Biotherapeutics NV's value of 25.95% is 57.4% below this benchmark. Historically, Lakefront Biotherapeutics NV's own Gross Margin % has ranged from 87.35 to 206.16 over the past decade. While the company's 10-year median is 97.33 vs. the industry median of 60.94, Lakefront Biotherapeutics NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lakefront Biotherapeutics NV's current Gross Margin % of 25.95% is 57.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Lakefront Biotherapeutics NV and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakefront Biotherapeutics NV's current Gross Margin % is 25.95%, which is 73% below median its own 10-year median of 97.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (WBO:LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is €104.25, compared to a current price of €25.50 — trading 75.5% below its estimated fair value. The current Gross Margin % is 25.95%, which is 73% below median its 10-year median of 97.33 and 57.4% below the Biotechnology industry median of 60.94. Lakefront Biotherapeutics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (WBO:LKFT), the current Gross Margin % is 25.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (WBO:LKFT) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of €25.50 is trading 75.5% below its estimated GF Value™ of €104.25.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for WBO:LKFT:
Gross Margin %: 25.95% (73% below median its 10-year median of 97.33)
GF Value™: €104.25 vs. price of €25.50 (75.5% below fair value)
Industry Position: 57.4% below the Biotechnology median (#35 of 738)
No single metric tells the full story. See the WBO:LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
60GF Score
Get the complete analysis for WBO:LKFT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:LKFT has been successfully added to your 
